BioSpace News Archive

IsoPlexis announced that its IsoSpark system has been named a winner in the 2021 BIG Innovation Awards presented by the Business Intelligence Group.

National survey finds 75% of those managing hypertension would measure heart vitals more often with passive monitoring devices

Enveric Biosciences Inc. (NASDAQ: ENVB), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 2,221,358 shares of Enver

Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today it has closed a $44 million Series A-1 financing. “Over the past two years, Elucida Oncology has successfully evolved to forge two paths in the world of precision oncology with its proprietary C’Dot platform. As our collaborators at leading research institutions continue to push the boundary of C’Dots’ potential in diagn

- Completion of maralixibat rolling NDA targeted for Q1 2021 - Expecting first-patient-in for volixibat studies in ICP and PSC, and maralixibat study in biliary atresia in Q1 2021 - Launching volixibat primary biliary cholangitis program in H2 2021 - European commercial leader hired in anticipation of potential approval of maralixibat

Rezolute, Inc. (Nasdaq: RZLT), today announced the initiation of dosing in a Phase 1 first-in-human clinical study of RZ402, an investigational oral plasma kallikrein inhibitor (PKI), for the treatment of diabetic macular edema (DME).

Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as “Cipla” today announced that it will participate at the 39th Annual J.P. Morgan Healthcare Conference, which is the largest healthcare investment symposium in the industry.

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 3,188,776 American Depositary Shares (ADSs) of the Company,

Turn Biotechnologies, a company developing medicines for currently untreatable age-related conditions, announced that it has acquired the global rights for new technology that reprograms cells to undo many of the effects of aging.

Milestone Scientific Inc. (NYSE American:MLSS) , a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced that it has begun selling CompuFlo® Epidural and CathCheck disposables to Regional Medical Center (RMC) , a premier regional healthcare system in South Carolina. Arjan Haverhals, President of Milestone Scientific, stated, “I would like to thank the entire anes